THE EFFICACY OF HIGH-DOSE SIMVASTATIN IN ACUTE PERIOD OF ISCHEMIC STROKE

<p>Aim. To estimate in a 12-month study mortality and frequency of recurrent cardiovascular events, dynamics of neurological deficit and endothelial dysfunction in patients with the first-time ischemic stroke treated with simvastatin 40 mg/day in acute period of the disease. Materials and meth...

Full description

Bibliographic Details
Main Authors: V. V. Yakusevich, A. Yu. Malygin, S. V. Lychenko, A. S. Petrochenko, A. V. Kabanov
Format: Article
Language:English
Published: Столичная издательская компания 2015-12-01
Series:Рациональная фармакотерапия в кардиологии
Subjects:
Online Access:http://www.rpcardio.ru/jour/article/view/393
_version_ 1797712015412690944
author V. V. Yakusevich
A. Yu. Malygin
S. V. Lychenko
A. S. Petrochenko
A. V. Kabanov
author_facet V. V. Yakusevich
A. Yu. Malygin
S. V. Lychenko
A. S. Petrochenko
A. V. Kabanov
author_sort V. V. Yakusevich
collection DOAJ
description <p>Aim. To estimate in a 12-month study mortality and frequency of recurrent cardiovascular events, dynamics of neurological deficit and endothelial dysfunction in patients with the first-time ischemic stroke treated with simvastatin 40 mg/day in acute period of the disease. Materials and methods. The efficacy of high-dose simvastatin (40 mg/day) therapy initiated in acute stage of ischemic stroke was evaluated in 12-month comparative randomized study. Patients of the first group (n=97) received standard stroke therapy , and patients of the second group (n=86) also received standard treatment and simvastatin additionally. Combined endpoint (cardiovascular death + recurrent cardiovascular events + necessity of readmission), dynamics of neurological status and endothelial function were considered.  Results. Primary combined endpoint was achieved in 66 cases in the first group (68.04%) and in 47 (54.65%) in the second one (p=0.043). Neurological status evaluated by National Institutes of Health Stroke Scale (NIHSS), Mini-Mental State Examination (MMSE) scale, and Scandinavian scales had a faster positive dynamics in patients receiving simvastatin. The same patients revealed more intense and quick decrease in desquamated plasma endotheliocytes. Conclusion. Simvastatin 40 mg/day prescribed along with neuroprotective and antihypertensive treatment in acute stage of ischemic stroke leads to lowering of recurrent cardiovascular events number, positive dynamics of neurological status, regression of endothelial dysfunction reflected by significant decrease in number of circulating desquamated endotheliocytes.</p>
first_indexed 2024-03-12T07:15:33Z
format Article
id doaj.art-adaa16e690724c5abbf30aeac20e478c
institution Directory Open Access Journal
issn 1819-6446
2225-3653
language English
last_indexed 2024-03-12T07:15:33Z
publishDate 2015-12-01
publisher Столичная издательская компания
record_format Article
series Рациональная фармакотерапия в кардиологии
spelling doaj.art-adaa16e690724c5abbf30aeac20e478c2023-09-02T22:52:11ZengСтоличная издательская компанияРациональная фармакотерапия в кардиологии1819-64462225-36532015-12-018141610.1234/1819-6446-2012-1-4-16393THE EFFICACY OF HIGH-DOSE SIMVASTATIN IN ACUTE PERIOD OF ISCHEMIC STROKEV. V. Yakusevich0A. Yu. Malygin1S. V. Lychenko2A. S. Petrochenko3A. V. Kabanov4Ярославская государственная медицинская академияГ ородская клиническая больница № 8 г . ЯрославльЯрославская государственная медицинская академияЯрославская государственная медицинская академияЯрославская государственная медицинская академия<p>Aim. To estimate in a 12-month study mortality and frequency of recurrent cardiovascular events, dynamics of neurological deficit and endothelial dysfunction in patients with the first-time ischemic stroke treated with simvastatin 40 mg/day in acute period of the disease. Materials and methods. The efficacy of high-dose simvastatin (40 mg/day) therapy initiated in acute stage of ischemic stroke was evaluated in 12-month comparative randomized study. Patients of the first group (n=97) received standard stroke therapy , and patients of the second group (n=86) also received standard treatment and simvastatin additionally. Combined endpoint (cardiovascular death + recurrent cardiovascular events + necessity of readmission), dynamics of neurological status and endothelial function were considered.  Results. Primary combined endpoint was achieved in 66 cases in the first group (68.04%) and in 47 (54.65%) in the second one (p=0.043). Neurological status evaluated by National Institutes of Health Stroke Scale (NIHSS), Mini-Mental State Examination (MMSE) scale, and Scandinavian scales had a faster positive dynamics in patients receiving simvastatin. The same patients revealed more intense and quick decrease in desquamated plasma endotheliocytes. Conclusion. Simvastatin 40 mg/day prescribed along with neuroprotective and antihypertensive treatment in acute stage of ischemic stroke leads to lowering of recurrent cardiovascular events number, positive dynamics of neurological status, regression of endothelial dysfunction reflected by significant decrease in number of circulating desquamated endotheliocytes.</p>http://www.rpcardio.ru/jour/article/view/393ишемический инсультсимвастатинвысокая дозаэндотелиальная дисфункциясердечно-сосудистые события
spellingShingle V. V. Yakusevich
A. Yu. Malygin
S. V. Lychenko
A. S. Petrochenko
A. V. Kabanov
THE EFFICACY OF HIGH-DOSE SIMVASTATIN IN ACUTE PERIOD OF ISCHEMIC STROKE
Рациональная фармакотерапия в кардиологии
ишемический инсульт
симвастатин
высокая доза
эндотелиальная дисфункция
сердечно-сосудистые события
title THE EFFICACY OF HIGH-DOSE SIMVASTATIN IN ACUTE PERIOD OF ISCHEMIC STROKE
title_full THE EFFICACY OF HIGH-DOSE SIMVASTATIN IN ACUTE PERIOD OF ISCHEMIC STROKE
title_fullStr THE EFFICACY OF HIGH-DOSE SIMVASTATIN IN ACUTE PERIOD OF ISCHEMIC STROKE
title_full_unstemmed THE EFFICACY OF HIGH-DOSE SIMVASTATIN IN ACUTE PERIOD OF ISCHEMIC STROKE
title_short THE EFFICACY OF HIGH-DOSE SIMVASTATIN IN ACUTE PERIOD OF ISCHEMIC STROKE
title_sort efficacy of high dose simvastatin in acute period of ischemic stroke
topic ишемический инсульт
симвастатин
высокая доза
эндотелиальная дисфункция
сердечно-сосудистые события
url http://www.rpcardio.ru/jour/article/view/393
work_keys_str_mv AT vvyakusevich theefficacyofhighdosesimvastatininacuteperiodofischemicstroke
AT ayumalygin theefficacyofhighdosesimvastatininacuteperiodofischemicstroke
AT svlychenko theefficacyofhighdosesimvastatininacuteperiodofischemicstroke
AT aspetrochenko theefficacyofhighdosesimvastatininacuteperiodofischemicstroke
AT avkabanov theefficacyofhighdosesimvastatininacuteperiodofischemicstroke
AT vvyakusevich efficacyofhighdosesimvastatininacuteperiodofischemicstroke
AT ayumalygin efficacyofhighdosesimvastatininacuteperiodofischemicstroke
AT svlychenko efficacyofhighdosesimvastatininacuteperiodofischemicstroke
AT aspetrochenko efficacyofhighdosesimvastatininacuteperiodofischemicstroke
AT avkabanov efficacyofhighdosesimvastatininacuteperiodofischemicstroke